×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMRX – immuneering corporation - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/11
10:32 am
imrx
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
High
Report
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
1/10
07:02 pm
imrx
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
High
Report
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
1/8
05:51 pm
imrx
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
Low
Report
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
1/7
04:00 pm
imrx
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
High
Report
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
12/30
03:52 pm
imrx
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]
Low
Report
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]
12/23
09:02 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
Medium
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
12/23
08:00 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Medium
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
12/20
01:30 am
imrx
Immuneering (NASDAQ:IMRX) was downgraded by analysts at Wall Street Zen<
Medium
Report
Immuneering (NASDAQ:IMRX) was downgraded by analysts at Wall Street Zen<
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:05 pm
imrx
immuneering corporation - class a
MISS
Report
-0.3%
immuneering corporation - class a
8/13/2025
04:05 pm
imrx
immuneering corporation - class a
IN-LINE
Report
-3.8%
immuneering corporation - class a
5/5/2025
04:05 pm
imrx
immuneering corporation - class a
MISS
Report
-4.8%
immuneering corporation - class a
3/20/2025
04:05 pm
imrx
immuneering corporation - class a
MISS
Report
9.1%
immuneering corporation - class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/16
04:08 pm
imrx
Form 4 Immuneering Corp For: Jan 15 Filed by: Hall Brett Matthew
Low
Report
Form 4 Immuneering Corp For: Jan 15 Filed by: Hall Brett Matthew
1/15
01:23 pm
imrx
Form SCHEDULE 13G/A Immuneering Corp Filed by: Empery Asset Management, LP
Low
Report
Form SCHEDULE 13G/A Immuneering Corp Filed by: Empery Asset Management, LP
1/15
08:06 am
imrx
Form 4 Immuneering Corp For: Jan 13 Filed by: Neufeld Leah R
Low
Report
Form 4 Immuneering Corp For: Jan 13 Filed by: Neufeld Leah R
1/14
08:10 am
imrx
Form 4 Immuneering Corp For: Jan 12 Filed by: Feinberg Peter
Medium
Report
Form 4 Immuneering Corp For: Jan 12 Filed by: Feinberg Peter
1/7
04:10 pm
imrx
Form 8-K Immuneering Corp For: Jan 07
High
Report
Form 8-K Immuneering Corp For: Jan 07
1/2
04:56 pm
imrx
Form 4 Immuneering Corp For: Jan 01 Filed by: KEATING LAURIE
Low
Report
Form 4 Immuneering Corp For: Jan 01 Filed by: KEATING LAURIE
1/2
04:50 pm
imrx
Form 4 Immuneering Corp For: Jan 01 Filed by: Feinberg Peter
Neutral
Report
Form 4 Immuneering Corp For: Jan 01 Filed by: Feinberg Peter
11/12
04:19 pm
imrx
Form 10-Q Immuneering Corp For: Sep 30
Low
Report
Form 10-Q Immuneering Corp For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: